Successful management of acute renal failure after high-dose methotrexate in a patient with relapsed osteosarcoma
Visualizar/abrir
Data
2008Autor
Tipo
Assunto
Abstract
High-dose methotrexate (MTX) is frequently included in the treatment of osteosarcoma [1]. Following intravenous high dosages, approximately 50 to 60% of this drug is bound to plasma proteins and more than 50% of MTX is excreted unchanged in the urine [2]. The most common side effects of MTX are mucositis of varying degrees and liver toxicity. Leukopenia, thrombocytopenia, severe mucositis, diarrhea, skin rash or renal dysfunction are not usually observed if prevention based on hydration and uri ...
High-dose methotrexate (MTX) is frequently included in the treatment of osteosarcoma [1]. Following intravenous high dosages, approximately 50 to 60% of this drug is bound to plasma proteins and more than 50% of MTX is excreted unchanged in the urine [2]. The most common side effects of MTX are mucositis of varying degrees and liver toxicity. Leukopenia, thrombocytopenia, severe mucositis, diarrhea, skin rash or renal dysfunction are not usually observed if prevention based on hydration and urine alkalization are adequately administrated [2, 3]. The reported incidence of acute renal failure (ARF) due to MTX is about 1.8% [4]. The mechanism of renal damage seems to be the intratubular precipitation of crystals produced by MTX and the consequence is usually a persistence of high serum levels of the drug [5]. The aim of this report is to describe the management of a patient who developed ARF following high dose MTX administration. ...
Contido em
The american journal of case reports. Smithtow, International Scientific Literature. Vol. 9 (2008), CR93-96
Origem
Estrangeiro
Coleções
-
Artigos de Periódicos (40305)Ciências da Saúde (10773)
Este item está licenciado na Creative Commons License